Wantai Bio Terminates Major HPV Vaccine Collaboration with GSK

Announcement on the evening of July 22,Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SH)’s wholly-owned subsidiary, Wantai Canghai, and GSK have decided to discontinue the development and commercialization cooperation of the HPV9-AS04 candidate vaccine under the "Cooperation Agreement."Notice of Termination of the "Cooperation Agreement" signed on July 20, 2024.

GSK(referred to as GSK) is aA global leading pharmaceutical technology company,Committed to providing better healthcare solutions for patients worldwide, with its headquarters located in the UK. GSK's product portfolio covers areas such as pharmaceuticals, vaccines, and consumer goods. In terms of pharmaceuticals, the company boasts a variety of best-selling drugs, including the antidepressant Wellbutrin and the antibiotic Zyvox. Additionally, GSK holds a leading position in the vaccine sector, with its vaccine products targeting various diseases.Vaccines for diseases such as pneumonia, influenza, and human papillomavirus.